FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-11

Price

$14.37

+0.07%

Score5.2Watchlist

Signals5/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 5

Volume1.4xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is trading in a heavily compressed, low-volatility state because it is entirely anchored to its pending $14.50 all-cash acquisition by BioMarin Pharmaceutical. Recent search findings confirm that FOLD stockholders officially approved the merger on March 3, 2026, explaining the stock's QUIET_STORM and PERFECT_STACK signals as the arbitrage spread mechanically tightens. Furthermore, this M&A catalyst completely overrides the current RISK_OFF geopolitical macro regime, offering absolute insulation from broader market volatility. Our conviction is exceptionally high that the stock will remain pinned near $14.37, acting as a short-duration cash proxy until the deal closes in Q2 2026.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKWEAK FINISH

Key Takeaways

Actionable Thesis: FOLD is a pure merger arbitrage play anchored to a $14.50 buyout, currently offering a highly probable but marginal $0.13 spread.
Key Risk: The only material downside risk is an unexpected regulatory challenge (e.g., FTC block) that derails the stockholder-approved acquisition.
What to Watch: Monitor regulatory filings and BioMarin press releases for the final Q2 2026 closing date, utilizing $14.30 as the hard deal-break support line.

← Back to 2026-03-11 View Full FOLD History →Yahoo Finance &nearr;